Board of Directors

At Quest Diagnostics, we recognize the importance of good corporate governance and value the leadership and input of the independent members of our Board of Directors. The Board has revised its leadership structure from time to time and retains the flexibility to revise its leadership structure if, in the exercise of its fiduciary duty, the Board believes that such revision is appropriate.

Our Lead Independent Director has a robust set of responsibilities, set forth in our Corporate Governance Guidelines. The principal responsibilities of the Lead Independent Director include:

  • Participate with the Chairman of the Board and CEO in the preparation of the agendas for Board meetings, and have the authority to call meetings of the non-management directors;
  • Serve as a member of the Board’s Executive Committee;
  • Coordinate providing timely feedback from the directors to the Chairman of the Board;
  • Preside over all executive sessions of the non-management directors and all Board meetings in the absence of the Chairman of the Board;
  • Take a leading role in the process of evaluating the Board, and lead the non-management directors in the annual evaluation of the performance of the President and CEO;
  • Interview candidates for the Board;
  • Serve as the principal contact for shareholder communications with the non-management directors; and
  • Monitor, and if appropriate discuss with the other non-management directors, communications received from shareholders and others.

We also have other mechanisms in place to promote the appropriate level of independence and oversight in Board decisions:

  • Our Corporate Governance Guidelines provide that at least a majority of our directors shall be independent. At this time all directors except for two are independent and all the members of the Audit and Finance, Compensation, Cybersecurity, Governance and Quality and Compliance Committees also are independent.
  • The Board and each of its committees have complete access to management and the authority to retain independent advisors, as they deem appropriate.
  • We have published procedures for interested parties, including shareholders, to communicate with our directors.
  • The Compensation Committee has retained the services of, and regularly consults with, an independent compensation consultant.

For information regarding contacting our Lead Independent Director, or any other director, click here.

James E. Davis, Chairman, CEO and President


Jim Davis is Chairman, CEO and President of Quest Diagnostics. He assumed the role of CEO and President on November 1, 2022, and then took on the additional title of Chairman on April 1, 2023. Jim joined Quest in April 2013 and initially served as Senior Vice President, Diagnostic Services. He was named Senior Vice President, Operations in February 2014 and was elected CEO and President in February 2022. Before joining Quest, he served as CEO of InSightec, Inc., a medical device company. Prior to that, Jim held senior management positions in a two-decade career in General Electric’s aviation and healthcare businesses, including leading GE’s MRI business for five years. Before GE, Jim led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc. Jim holds a master’s degree in management from the Sloan School of Management at Massachusetts Institute of Technology, a master’s degree in science from MIT and a bachelor's degree in aeronautical engineering from the University of Michigan.

Luis A. Diaz, Jr., M.D., Director


Luis A. Diaz, Jr., M.D., has been the head of the division of solid tumor oncology at the Memorial Sloan Kettering Cancer Center since December 2016. From 2004 to December 2016, he was a faculty member and physician at the Johns Hopkins University School of Medicine.  He has founded several biotechnology companies, including Epitope, Inostics, PapGene (Thrive) and Personal Genome Diagnostics, Inc. Dr. Diaz’s early work provided the first definitive evidence for using circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease. He discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors, which led to the first tumor agnostic FDA approval for tumors with this genetic lesion and the first cancer study, published in 2022, that resulted in a 100% complete remission rate. Dr. Diaz has served on the board of Jounce Therapeutics, Inc. since 2017. He is the recipient of numerous awards and honors and in 2021 was appointed by President Biden to the National Cancer Advisory Board of the National Institutes of Health. Dr. Diaz has been a director of Quest Diagnostics since May 2023. He has extensive experience in medicine, science and healthcare and strong management and strategic planning experience with enterprises engaged in medicine, science and healthcare.

Tracey C. Doi, Director


Ms. Doi retired as Chief Financial Officer and Group Vice President of Toyota Motor North America, Inc. in 2022, after serving nearly twenty years as CFO. Ms. Doi joined Toyota in 2000 as Vice President, Corporate Controller and her responsibilities continued to expand upon her elevation to CFO in 2003. She serves as an independent trustee of SunAmerica Series Trust and Season Series Trust. Ms. Doi served on the board of City National Bank, a Royal Bank of Canada Company from 2016 to 2021. Ms. Doi served on the Federal Reserve Bank of San Francisco Economic Advisory Council from 2009 to 2016. She is an active board member of the National Asian/Pacific Islander American Chamber of Commerce Foundation, National Association of Corporate Directors North Texas, 50/50 Women on Boards, International Women’s Forum – Dallas and the Japanese American National Museum.

Ms. Doi has extensive executive experience, including in corporate finance, general management, strategic planning, operations, risk, enterprise systems, consumer focus, business analytics and transformation, with a multinational corporation operating in a complex industry.

Vicky B. Gregg, Director


Ms. Gregg is a cofounder/partner of Guidon Partners LLC.  She retired as Chief Executive Officer of Blue Cross Blue Shield of Tennessee in 2012. Prior to becoming CEO in 2003, Ms. Gregg served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg served as a member of the U.S. National Institutes of Health Commission on Systemic Interoperability. She currently serves on the boards of Acadia Healthcare Company, Inc., Erlanger Health System and the Electric Power Board of Chattanooga, as well as the boards of several private companies, including MyEyeDr. Previously, Ms. Gregg served on several national boards, including TeamHealth Holdings, Inc. from 2013 to 2017 and First Horizon National Corporation from 2011 to 2015.  She has also served as Chair of America’s Health Insurance Plans, as a member of the BlueCross BlueShield Association, as Chair of the National Institute for Healthcare Management, and as a member of the Healthcare Leadership Council.

Ms. Gregg has extensive executive and advisory experience, including in general management and strategic planning, with a range of health care organizations, and extensive experience with healthcare issues and the operation of the U.S. healthcare system, including as a practicing nurse.

Wright L. Lassiter, III, Director


Wright L. Lassiter, III, in August 2022 became CEO of CommonSpirit Health, one of the country’s largest and most diverse health care organizations, with a network of 140 hospitals and more than 1,500 care sites across 21 states. Prior to joining CommonSpirit Health, he was President and CEO of Henry Ford Health System in Detroit, Michigan from 2014 to 2022. Prior to that he was CEO of Alameda Health System in Oakland, California from 2005 to 2014. Mr. Lassiter currently serves on the board of Fortive Corporation and is the Chair of the American Hospital Association.  Previously he served on the boards of DT Midstream, Inc. (2021 – 2023) and Henry Ford Health System and as Vice Chair for the Federal Reserve Bank of Chicago.

Mr. Lassiter has extensive executive experience in the U.S. healthcare system, including in governance, strategic planning, market expansion, mergers and acquisitions, performance improvement and corporate turnaround.

Timothy L. Main, Director


Mr. Main has been the Non-Executive Chairman of WNS (Holdings) Limited since September 2021. From 2000 until 2013 he was the Chief Executive Officer, and from 2013 until 2021 the non-executive Chairman of the Board of Directors, of Jabil, Inc., an electronic product solutions company providing comprehensive electronics design, manufacturing and management services to global electronics and technology companies. As CEO, Mr. Main led Jabil’s growth strategy, increasing annual revenues nearly fivefold to reach $17 billion in 2012, and expanding in Asia and other emerging markets. Mr. Main currently serves on the board of SCP & CO Healthcare Acquisition Co. He has been a director of Quest Diagnostics since January 2014. He has extensive executive experience, including in international, capital markets, technology, operations, corporate governance and general management in a complex industry.

Denise M. Morrison, Director


Ms. Morrison is the founder of Denise Morrison & Associates, LLC, a consulting firm.  She retired in 2018 as President and Chief Executive Officer of Campbell Soup Company. Ms. Morrison joined Campbell in 2003, where she held positions of increasing responsibility. Prior to joining Campbell, she held executive management positions at Kraft Foods, Inc. from 2001 to 2003. Ms. Morrison is a director of Visa, Inc. and MetLife, Inc., and served as a director of Campbell Soup Company from 2010 to 2018 and a director of The Goodyear Tire & Rubber Company from 2005 to 2010. She is a member of the Board of Trustees for Boston College, the Business Council and the Advisory Council for Just Capital. Ms. Morrison previously served on the Advisory Board for Tufts Friedman School of Nutrition Science and Policy; the New Jersey Restart and Recovery Commission; President Trump’s Manufacturing Jobs Initiative; and President Obama’s Export Council. Ms. Morrison has been a director of Quest Diagnostics since February 2019. She has extensive executive experience, including in general management and strategic planning, operations and marketing, with multinational corporations operating in consumer-focused, regulated industries.

Gary M. Pfeiffer , Director


Mr. Pfeiffer retired in 2006 as the Senior Vice President and Chief Financial Officer of E.I. du Pont de Nemours and Company. He joined DuPont in 1974, where he held positions of increasing responsibility in finance and international operations, as well as in various DuPont divisions. Mr. Pfeiffer served as Secretary of Finance for the state of Delaware from January through June 2009. Mr. Pfeiffer served as a director and Chair of the Board of InterNAP Corporation from 2007 to 2020, a director of TerraVia Holdings, Inc. from 2014 to 2017 and Talbots, Inc. from 2005 to 2012. He served as the non‐executive Chair of the Board of Directors of Christiana Care Health System, a regional hospital system located in Delaware, from 2012 to 2016. Mr. Pfeiffer has been a director of Quest Diagnostics since December 2004. He has extensive executive experience, including in corporate finance, accounting, international operations, and strategic planning, with a multinational corporation operating in complex industries.

Timothy M. Ring, Lead Independent Director


Mr. Ring retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. He is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and CIT Group Inc. from 2005 to 2009. Mr. Ring is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India.

Mr. Ring has extensive executive experience, including in corporate governance, strategic planning and international operations, with a multinational corporation operating in the healthcare industry.

Gail R. Wilensky, Ph.D., Director


Dr. Wilensky, is a Senior Fellow at Project HOPE, an international non-profit health foundation, which she joined in 1993. From 2008 through 2009, Dr. Wilensky served as President of the Defense Health Board, an advisory board in the Department of Defense. From 1997 to 2001, she was the chair of the Medicare Payment Advisory Commission. From 1995 to 1997, she chaired the Physician Payment Review Commission. In 1992 and 1993, Dr. Wilensky served as a deputy assistant to the President of the United States for policy development relating to health and welfare issues. From 1990 to 1992, she was the administrator of the Health Care Financing Administration where she directed the Medicare and Medicaid programs. Dr. Wilensky is a director of ViewRay, Inc. She served as a director of UnitedHealthcare Group Incorporated from 2005 to 2022, Manor Care Inc. from 1998 until 2009, Gentiva Health Services, Inc. from 2000 until 2009, Cephalon Inc. from 2002 to 2011 and SRA International, Inc. from 2005 to 2011. Dr. Wilensky also served as a Commissioner of the World Health Organization’s Commission on the Social Determinants of Health and as the Non-Department Co-Chair of the Defense Department’s Task Force on the Future of Military Health Care. She has been a director of Quest Diagnostics since January 1997. Dr. Wilensky has extensive experience, including in strategic planning, as a senior advisor to the U.S. government and private enterprises regarding healthcare issues and the operation of the U.S. healthcare system.